This page lists ClinicalTrials.gov records that name Survodutide among their listed interventions. Titles, phases, and status are taken from the official registry. It is a research reference only. It is not medical advice, and it does not offer or recommend any product for human or veterinary use.
Search
Compound
All compounds
Survodutide
Phase
All phases
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Observational
Not applicable
Expanded access
Status
All statuses
No registered studies match that search or filter.
Not yet recruiting Phase 3 Survodutide
NCT ID NCT07850063
Sponsor Boehringer Ingelheim
Registry dates 2026-11-18 – 2029-04-29
Enrollment 600 registered participants
Locations United States, China, Germany +2 more
Conditions listed Obesity; Metabolic Dysfunction-associated Steatotic Liver Disease Registry record on ClinicalTrials.gov
Not yet recruiting Phase 3 Survodutide
NCT ID NCT07855900
Sponsor Boehringer Ingelheim
Registry dates 2026-11-07 – 2029-11-06
Enrollment 350 registered participants
Locations United States
Conditions listed Obesity Registry record on ClinicalTrials.gov
Not yet recruiting Phase 3 Survodutide
NCT ID NCT07850050
Sponsor Boehringer Ingelheim
Registry dates 2026-10-31 – 2028-07-26
Enrollment 600 registered participants
Locations United States, United Kingdom
Conditions listed Obesity Registry record on ClinicalTrials.gov
Active, not recruiting Phase 1 Survodutide
NCT ID NCT07768813
Sponsor Boehringer Ingelheim
Registry dates 2026-09-02 – 2026-12-22
Enrollment 44 registered participants
Locations Germany
Conditions listed Healthy; Obesity Registry record on ClinicalTrials.gov
Recruiting Phase 3 Survodutide
NCT ID NCT07754461
Sponsor Boehringer Ingelheim
Registry dates 2026-08-24 – 2028-05-01
Enrollment 600 registered participants
Locations United States, Australia, Canada +3 more
Conditions listed Type 2 Diabetes Registry record on ClinicalTrials.gov
Completed Phase 1 Survodutide
NCT ID NCT07413913
Sponsor Boehringer Ingelheim
Registry dates 2026-03-03 – 2026-06-11
Enrollment 56 registered participants
Locations Germany
Conditions listed Healthy; Obesity Registry record on ClinicalTrials.gov
Not yet recruiting Phase 2 Survodutide
NCT ID NCT07206290
Sponsor University Medical Center Groningen
Registry dates 2026-03-02 – 2027-11-30
Enrollment 120 registered participants
Conditions listed Chronic Kidney Disease Registry record on ClinicalTrials.gov
Completed Phase 1 Survodutide
NCT ID NCT07221591
Sponsor Boehringer Ingelheim
Registry dates 2025-11-05 – 2026-07-28
Enrollment 100 registered participants
Locations Germany
Conditions listed Healthy Registry record on ClinicalTrials.gov
Completed Phase 1 Survodutide
NCT ID NCT07071974
Sponsor Boehringer Ingelheim
Registry dates 2025-07-28 – 2025-10-28
Enrollment 16 registered participants
Locations Germany
Conditions listed Healthy Registry record on ClinicalTrials.gov
Active, not recruiting Phase 1 Semaglutide Survodutide
NCT ID NCT06745284
Sponsor Boehringer Ingelheim
Registry dates 2025-03-26 – 2026-12-01
Enrollment 64 registered participants
Locations United States
Conditions listed Obesity Registry record on ClinicalTrials.gov
Completed Phase 1 Survodutide
NCT ID NCT06772532
Sponsor Boehringer Ingelheim
Registry dates 2025-02-10 – 2025-06-10
Enrollment 30 registered participants
Locations Germany
Conditions listed Healthy Registry record on ClinicalTrials.gov
Recruiting Phase 3 Survodutide
NCT ID NCT06632457
Sponsor Boehringer Ingelheim
Registry dates 2024-11-12 – 2029-06-05
Enrollment 1,590 registered participants
Locations United States, Argentina, Australia +34 more
Conditions listed Metabolic Dysfunction Associated Steatohepatitis Registry record on ClinicalTrials.gov
Active, not recruiting Phase 1 Survodutide
NCT ID NCT05202353
Sponsor Boehringer Ingelheim
Registry dates 2024-11-01 – 2027-02-03
Enrollment 29 registered participants
Locations Netherlands
Conditions listed Obesity Registry record on ClinicalTrials.gov
Recruiting Phase 3 Survodutide
NCT ID NCT06632444
Sponsor Boehringer Ingelheim
Registry dates 2024-10-14 – 2031-12-27
Enrollment 1,800 registered participants
Locations United States, Argentina, Australia +34 more
Conditions listed Metabolic Dysfunction Associated Steatohepatitis (MASH); Liver Fibrosis Registry record on ClinicalTrials.gov
Completed Phase 1 Survodutide
NCT ID NCT06564441
Sponsor Boehringer Ingelheim
Registry dates 2024-10-01 – 2026-01-05
Enrollment 34 registered participants
Locations Belgium
Conditions listed Overweight; Obesity Registry record on ClinicalTrials.gov
Completed Phase 1 Survodutide
NCT ID NCT06492135
Sponsor Boehringer Ingelheim
Registry dates 2024-08-12 – 2025-04-15
Enrollment 30 registered participants
Locations China
Conditions listed Overweight; Obesity Registry record on ClinicalTrials.gov
Completed Phase 1 Survodutide
NCT ID NCT06352411
Sponsor Boehringer Ingelheim
Registry dates 2024-05-15 – 2025-09-16
Enrollment 42 registered participants
Locations Germany
Conditions listed Healthy; Renal Impairment Registry record on ClinicalTrials.gov
Completed Phase 1 Survodutide
NCT ID NCT06352424
Sponsor Boehringer Ingelheim
Registry dates 2024-04-30 – 2025-02-24
Enrollment 23 registered participants
Locations Germany
Conditions listed Obesity Registry record on ClinicalTrials.gov
Completed Phase 3 Survodutide
NCT ID NCT06309992
Sponsor Boehringer Ingelheim
Registry dates 2024-04-02 – 2025-12-02
Enrollment 218 registered participants
Locations United States, Spain
Conditions listed Obesity; Non-Alcoholic SteatoHepatitis (NASH) Registry record on ClinicalTrials.gov
Completed Phase 1 Survodutide
NCT ID NCT06200467
Sponsor Boehringer Ingelheim
Registry dates 2024-03-13 – 2025-10-22
Enrollment 110 registered participants
Locations Germany
Conditions listed Overweight; Obesity Registry record on ClinicalTrials.gov
Completed Phase 3 Survodutide
NCT ID NCT06214741
Sponsor Boehringer Ingelheim
Registry dates 2024-02-06 – 2026-01-28
Enrollment 307 registered participants
Locations China
Conditions listed Obesity; Overweight Registry record on ClinicalTrials.gov
Completed Phase 3 Survodutide
NCT ID NCT06176365
Sponsor Boehringer Ingelheim
Registry dates 2024-01-16 – 2025-12-03
Enrollment 274 registered participants
Locations Japan
Conditions listed Obesity Registry record on ClinicalTrials.gov
Completed Phase 1 Survodutide
NCT ID NCT05896384
Sponsor Boehringer Ingelheim
Registry dates 2023-12-21 – 2025-03-26
Enrollment 32 registered participants
Locations Germany
Conditions listed Healthy Registry record on ClinicalTrials.gov
Completed Phase 3 Survodutide
NCT ID NCT06066528
Sponsor Boehringer Ingelheim
Registry dates 2023-11-27 – 2026-04-01
Enrollment 755 registered participants
Locations United States, Australia, Belgium +16 more
Conditions listed Obesity; Diabetes Mellitus, Type 2 Registry record on ClinicalTrials.gov
Completed Phase 3 Survodutide
NCT ID NCT06066515
Sponsor Boehringer Ingelheim
Registry dates 2023-11-25 – 2026-02-20
Enrollment 726 registered participants
Locations United States, Australia, Belgium +11 more
Conditions listed Obesity Registry record on ClinicalTrials.gov